PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR

Maruhashi, Takumi; Shimizu, Kenji; Watada, Mizuki; Okazaki, Il-mi; Okazaki, Taku

doi:10.1016/j.bbrc.2019.02.004

Cited by 7 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 65 ] Similarly, cell co-culture in vitro also revealed that even under co-stimulation of GITR or CD27, the activation of T cells was inhibited by PD-1 effectively. [ 66 ] These results demonstrated that the combination of blockading PD-1 and triggering TNFRSF molecules is a rational therapeutic strategy of tumor treatment. Indeed, preclinical study of NSCLC mouse models revealed that a GITR agonist combined with anti-PD-1 and radiation therapy improved the survival significantly and produced tumor-free status in half the mice tested.…”

Section: Co-stimulatory T Lymphocyte Checkpointsmentioning

confidence: 99%

Emerging immunotherapy targets in lung cancer

Zhu

2020

Chinese Medical Journal

View full text Add to dashboard Cite

Immunotherapy has become the mainstay for lung cancer treatment, providing sustained therapeutic responses and improved prognosis compared with those obtained with surgery, chemotherapy, radiotherapy, and targeted therapy. It has the potential for anti-tumor treatment and killing tumor cells by activating human immunity and has moved the targets of anti-cancer therapy from malignant tumor cells to immune cell subsets. Two kinds of immune checkpoints, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1), are the main targets of current immunotherapy in lung cancer. Despite the successful outcomes achieved by immune checkpoint inhibitors, a small portion of lung cancer patients remain unresponsive to checkpoint immunotherapy or may ultimately become resistant to these agents as a result of the complex immune modulatory network in the tumor microenvironment. Therefore, it is imperative to exploit novel immunotherapy targets to further expand the proportion of patients benefiting from immunotherapy. This review summarizes the molecular features, biological function, and clinical significance of several novel checkpoints that have important roles in lung cancer immune responses beyond the CTLA-4 and PD-1/PD-L1 axes, including the markers of co-inhibitory and co-stimulatory T lymphocyte pathways and inhibitory markers of macrophages and natural killer cells.

show abstract

Section: Co-stimulatory T Lymphocyte Checkpointsmentioning

confidence: 99%

Emerging immunotherapy targets in lung cancer

Zhu

2020

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…High GITR levels have been reported on the surface of Tregs in mouse models but also on any activated T cells in humans, challenging its usefulness as a Treg marker [162]. Recently, PD-1 blockade and activation of GITR could synergistically induce the activation of T cells [163]. In addition, agonistic targeting of GITR was shown to augment TIL functionality in hepatocellular carcinoma [164].…”

Section: Immunotherapeutic Approaches Against Cancermentioning

confidence: 99%

Current Perspectives in Cancer Immunotherapy

Christofi

Baritaki

Falzone

et al. 2019

Cancers

165

121

View full text Add to dashboard Cite

Different immunotherapeutic approaches have proved to be of significant clinical value to many patients with different types of advanced cancer. However, we need more precise immunotherapies and predictive biomarkers to increase the successful response rates. The advent of next generation sequencing technologies and their applications in immuno-oncology has helped us tremendously towards this aim. We are now moving towards the realization of personalized medicine, thus, significantly increasing our expectations for a more successful management of the disease. Here, we discuss the current immunotherapeutic approaches against cancer, including immune checkpoint blockade with an emphasis on anti-PD-L1 and anti-CTLA-4 monoclonal antibodies. We also analyze a growing list of other co-inhibitory and co-stimulatory markers and emphasize the mechanism of action of the principal pathway for each of these, as well as on drugs that either have been FDA-approved or are under clinical investigation. We further discuss recent advances in other immunotherapies, including cytokine therapy, adoptive cell transfer therapy and therapeutic vaccines. We finally discuss the modulation of gut microbiota composition and response to immunotherapy, as well as how tumor-intrinsic factors and immunological processes influence the mutational and epigenetic landscape of progressing tumors and response to immunotherapy but also how immunotherapeutic intervention influences the landscape of cancer neoepitopes and tumor immunoediting.

show abstract

Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer

Lao

Liang

et al. 2023

Immunobiology

View full text Add to dashboard Cite

PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR

Cited by 7 publications

References 27 publications

Emerging immunotherapy targets in lung cancer

Emerging immunotherapy targets in lung cancer

Current Perspectives in Cancer Immunotherapy

Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer

Contact Info

Product

Resources

About